Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

111.78 +0.03 (+0.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
60 61 Next >
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
From Gilead Sciences, Inc.
Via Business Wire
3 Magnificent Dividend Stocks to Buy in October
These stocks come with great dividends and more. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study
Gilead Sciences Inc (NASDAQ: GILD) said it has  
Via Benzinga
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
Gilead Sciences Unusual Options Activity
Via Benzinga
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Gilead Sciences Adapts to Economic Shifts to Support Investor Confidence
By the end of today, September 28, 2023, Gilead Sciences (NASDAQ:GILD) is set to deliver a dividend payout of $0.75 per share, equating to an annualized dividend yield of 3.96%. 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Gilead Sciences Inc. (NASDAQ: GILD) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Many stocks have nosebleed valuations. But not these. 
Via The Motley Fool
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
Via Benzinga
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Good medicines aren't always good business. 
Via The Motley Fool
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains. 
Via MarketBeat
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food... 
Via FinancialNewsMedia
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy. 
Via Benzinga
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
What You Need to Know About Hepatitis C This Recovery Month
(BPT) - Hepatitis C (HCV) is often referred to as the 'silent disease' due to silent symptoms that may not appear until years after exposure. In fact, of the more than 2 million Americans who are... 
Via Brandpoint
How To Earn $500 A Month From Gilead Sciences Stock
Shares of Gilead Sciences, Inc (NASDAQ: GILD) are trading higher during Friday’s trading session, bolstered by the Bank of America Securities bullish outlook on the stock. 
Via Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,  
Via Benzinga
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
Gilead shares are on the rise amid an unexpected boon for its HIV treatment business. 
Via Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean... 
Via Benzinga
Gilead Prices $2 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS